GleamWall
中文EN

LCTX Lineage Cell Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 876343 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.2%
TTM net income YoY102.6%
TTM EPS YoY69.0%
Revenue 3-yr CAGR7.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-280.3%
Net margin16.2%
FCF margin-244.1%
EBITDA margin-273.3%

Returns

ROE3.9%
ROA1.8%
ROIC (approx.)-216.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio5.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-14.73x
Accruals ratio29.1%
Payout ratio—
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.43M$1.07M$1.73M$6.61M$3.68M$2.77M$1.50M$2.87M
Cost of revenue——————$36,000$154,000
Gross profit——————$1.47M$2.71M
R&D expense$3.82M$4.77M$4.23M$8.24M$3.27M$3.11M$3.11M$3.42M
SG&A expense$4.92M$5.22M$5.08M$4.85M$4.19M$4.56M$4.86M$4.40M
Operating income-$7.31M-$8.92M-$7.59M-$6.55M-$3.79M-$19.78M-$6.50M-$5.11M
Pretax income$4.71M——-$4.39M-$29.75M——-$3.25M
Income tax$484,000——-$5.28M$0——$0
Net income$4.23M$1.48M-$4.81M$851,000-$29.78M-$30.46M-$4.14M-$3.27M
EBITDA-$7.11M-$8.74M-$7.41M-$6.36M-$3.61M-$19.61M-$6.34M-$4.96M
EPS (basic)0.020.01-0.02—-0.13-0.13-0.02—
EPS (diluted)-0.03-0.03-0.03—-0.13-0.13-0.02—
Weighted avg. shares (diluted)259.07M261.47M261.18M—228.85M228.36M226.05M—
Balance sheet
Cash & equivalents$26.50M$37.35M$35.94M$40.79M$40.46M$42.27M$47.89M$46.35M
Short-term investments$18.68M$13.47M$17.44M$14.99M$23,000$17,000$19,000$2.02M
Receivables$1.33M$790,000$806,000$891,000$127,000$256,000$213,000$638,000
Current assets$47.77M$52.97M$56.16M$59.16M$42.26M$43.84M$49.98M$51.00M
PP&E, net$2.38M$2.52M$2.50M$2.57M$2.16M$2.25M$2.15M$2.25M
Goodwill$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M$10.67M
Intangibles$31.70M$31.70M$31.70M$31.70M$31.70M$31.70M$46.54M$46.54M
Total assets$100.11M$106.22M$109.53M$112.58M$89.64M$90.80M$111.75M$113.22M
Current liabilities$8.02M$8.02M$8.15M$11.37M$9.38M$10.76M$13.09M$13.98M
Total liabilities$34.17M$46.42M$56.84M$69.24M$68.84M$43.69M$34.10M$36.21M
Shareholders' equity$67.06M$60.92M$53.88M$44.55M$22.04M$48.38M$79.03M$78.38M
Shares outstanding252.91M252.91M249.30M243.12M230.33M228.36M228.36M220.42M
Cash flow statement
Operating cash flow-$5.62M-$7.24M-$8.08M-$4.88M-$3.62M-$5.54M-$4.89M-$6.35M
Capital expenditure$74,000$108,000$55,000$399,000$12,000$14,000$97,000$365,000
Free cash flow-$5.69M-$7.35M-$8.13M-$5.28M-$3.63M-$5.55M-$4.98M-$6.71M
Investing cash flow-$5.15M$3.96M-$2.33M-$15.33M-$12,000-$14,000$1.90M$2.63M
Financing cash flow-$23,000$4.47M$5.56M$20.38M$1.83M-$307,000$5.04M$21.73M
Depreciation & amortization$202,000$187,000$188,000$186,000$178,000$171,000$164,000$151,000
Stock-based compensation$1.70M$1.60M$1.17M$1.10M$1.20M$1.24M$1.22M$1.31M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.